Identifying patients infected with hepatitis B virus in sub-Saharan Africa: Potential for misclassification

ANRS 12240 VarBVA study

doi:https://doi.org/10.1016/j.diagmicrobio.2015.07.009

Identifying patients infected with hepatitis B virus in sub-Saharan Africa: Potential for misclassification

ANRS 12240 VarBVA study

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

Most research in sub-Saharan Africa establishes hepatitis B infection via one-time hepatitis B surface antigen (HBsAg) testing. Of 237 HIV-infected patients from two clinical trials testing HBsAg positive (MiniVidas®), 206 (86.9%) had validated serological tests using another assay (Architect). Discrepancies could be due to inactive infection, highlighting the importance of assessing hepatitis B virus infection phase.

Original language	English
Pages (from-to)	248-251
Number of pages	4
Journal	Diagnostic microbiology and infectious disease
Volume	83
Issue number	3
DOIs	https://doi.org/10.1016/j.diagmicrobio.2015.07.009
Publication status	Published - 1 Nov 2015
Externally published	Yes

Keywords

Adult
Africa South of the Sahara
Cohort Studies
DNA, Viral/blood
Female
HIV Infections/complications
Hepatitis B Antibodies/blood
Hepatitis B Surface Antigens/blood
Hepatitis B e Antigens/blood
Hepatitis B virus/isolation & purification
Hepatitis B/diagnosis
Humans
Male
Middle Aged
Young Adult

Access to Document

https://doi.org/10.1016/j.diagmicrobio.2015.07.009

Cite this

@article{ba1a52e4f52643b197f772f035e51389,

title = "Identifying patients infected with hepatitis B virus in sub-Saharan Africa: Potential for misclassification",

abstract = "Most research in sub-Saharan Africa establishes hepatitis B infection via one-time hepatitis B surface antigen (HBsAg) testing. Of 237 HIV-infected patients from two clinical trials testing HBsAg positive (MiniVidas{\textregistered}), 206 (86.9%) had validated serological tests using another assay (Architect). Discrepancies could be due to inactive infection, highlighting the importance of assessing hepatitis B virus infection phase.",

keywords = "Adult, Africa South of the Sahara, Cohort Studies, DNA, Viral/blood, Female, HIV Infections/complications, Hepatitis B Antibodies/blood, Hepatitis B Surface Antigens/blood, Hepatitis B e Antigens/blood, Hepatitis B virus/isolation & purification, Hepatitis B/diagnosis, Humans, Male, Middle Aged, Young Adult",

author = "Anders Boyd and Sarah Maylin and Raoul Moh and Delphine Gabillard and Herv{\'e} Menan and Nadia Mahjoub and Christine Danel and Xavier Anglaret and Eholi{\'e}, {Serge Paul} and {ANRS 12240 VarBVA study} and Pierre-Marie Girard and Fabien Zoulim and Constance Delaugerre and Karine Lacombe",

year = "2015",

month = nov,

day = "1",

doi = "https://doi.org/10.1016/j.diagmicrobio.2015.07.009",

language = "English",

volume = "83",

pages = "248--251",

journal = "Diagnostic microbiology and infectious disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Identifying patients infected with hepatitis B virus in sub-Saharan Africa

T2 - Potential for misclassification

AU - Boyd, Anders

AU - Maylin, Sarah

AU - Moh, Raoul

AU - Gabillard, Delphine

AU - Menan, Hervé

AU - Mahjoub, Nadia

AU - Danel, Christine

AU - Anglaret, Xavier

AU - Eholié, Serge Paul

AU - ANRS 12240 VarBVA study

AU - Girard, Pierre-Marie

AU - Zoulim, Fabien

AU - Delaugerre, Constance

AU - Lacombe, Karine

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Most research in sub-Saharan Africa establishes hepatitis B infection via one-time hepatitis B surface antigen (HBsAg) testing. Of 237 HIV-infected patients from two clinical trials testing HBsAg positive (MiniVidas®), 206 (86.9%) had validated serological tests using another assay (Architect). Discrepancies could be due to inactive infection, highlighting the importance of assessing hepatitis B virus infection phase.

AB - Most research in sub-Saharan Africa establishes hepatitis B infection via one-time hepatitis B surface antigen (HBsAg) testing. Of 237 HIV-infected patients from two clinical trials testing HBsAg positive (MiniVidas®), 206 (86.9%) had validated serological tests using another assay (Architect). Discrepancies could be due to inactive infection, highlighting the importance of assessing hepatitis B virus infection phase.

KW - Adult

KW - Africa South of the Sahara

KW - Cohort Studies

KW - DNA, Viral/blood

KW - Female

KW - HIV Infections/complications

KW - Hepatitis B Antibodies/blood

KW - Hepatitis B Surface Antigens/blood

KW - Hepatitis B e Antigens/blood

KW - Hepatitis B virus/isolation & purification

KW - Hepatitis B/diagnosis

KW - Humans

KW - Male

KW - Middle Aged

KW - Young Adult

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84943581531&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/26283522

U2 - https://doi.org/10.1016/j.diagmicrobio.2015.07.009

DO - https://doi.org/10.1016/j.diagmicrobio.2015.07.009

M3 - Article

C2 - 26283522

SN - 0732-8893

VL - 83

SP - 248

EP - 251

JO - Diagnostic microbiology and infectious disease

JF - Diagnostic microbiology and infectious disease

IS - 3

ER -

Identifying patients infected with hepatitis B virus in sub-Saharan Africa: Potential for misclassification

Abstract

Keywords

Access to Document

Other files and links

Cite this